A Prospective, Multicentre, Double-blind Randomized Controlled Clinical Study of the Efficacy and Safety of Taurine Combined With Serplulimab and Chemotherapy Versus Serplulimab Combined With Chemotherapy for Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
This project aims to evaluate the efficacy and safety of oral taurine supplementation combined with PD-1 inhibitor (serplulimab) and chemotherapy in inducing systemic CD8+ T cell responses and achieving improved gastric cancer patient outcomes than with serplulimab and chemotherapy alone.
• Age 18-75 years old, no gender limitation;
• Pathologically confirmed gastric or gastroesophageal junction adenocarcinoma with cTNM stage II/III，T≥3, N ≥0, M=0；
• Expected survival of ≥ 3 months;
• The tumor specimens were PD-L1 positive (CPS ≥ 1)；
• There is a measurable lesion with the possibility of radical R0 resection after evaluation by doctors；
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• Patients informed about the purpose and course of the study and provided a written consent to participate.